Ani Pharmaceuticals (ANIP) Non-Current Assets (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted Non-Current Assets of $674.9 million for Q1 2026, down 1.8% sequentially from $687.3 million in Q4 2025, and down 10.75% YoY from $756.1 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Non-Current Assets (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $674.9 million in Q1 2026.
- Quarterly Non-Current Assets fell 10.75% year-over-year to $674.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 6.38% YoY) and the FY2025 annual result came in at $687.3 million, down 9.09% from the prior year.
- Non-Current Assets declined to $674.9 million in Q1 2026 per ANIP's latest filing, from $687.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $766.1 million in Q3 2024 and troughed at $365.3 million in Q2 2024.
- A 5-year average of $536.8 million and a median of $429.7 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets soared 102.68% in 2025, then slipped 10.75% in 2026.
- Over 5 years, Non-Current Assets stood at $415.8 million in 2022, then fell by 7.51% to $384.6 million in 2023, then surged by 96.57% to $756.0 million in 2024, then retreated by 9.09% to $687.3 million in 2025, then decreased by 1.8% to $674.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $674.9 million, $687.3 million, and $709.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 2.96 Bn |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 668.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 668.68 Mn |
| Mar 31, 2026 | 674.89 Mn |
| Dec 31, 2025 | 687.26 Mn |
| Sep 30, 2025 | 709.75 Mn |
| Jun 30, 2025 | 740.37 Mn |
| Mar 31, 2025 | 756.14 Mn |
| Dec 31, 2024 | 756.01 Mn |
| Sep 30, 2024 | 766.08 Mn |
| Jun 30, 2024 | 365.29 Mn |
| Mar 31, 2024 | 373.97 Mn |
| Dec 31, 2023 | 384.61 Mn |
| Sep 30, 2023 | 392.69 Mn |
| Jun 30, 2023 | 400.03 Mn |
| Mar 31, 2023 | 400.47 Mn |
| Dec 31, 2022 | 415.83 Mn |
| Sep 30, 2022 | 429.73 Mn |
| Jun 30, 2022 | 428.94 Mn |
| Mar 31, 2022 | 443.45 Mn |
| Dec 31, 2021 | 449.82 Mn |
| Sep 30, 2021 | 279.07 Mn |